Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Am J Perinatol ; 2023 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-37279789

RESUMEN

OBJECTIVE: This study aimed to analyze characteristics of those seen for threatened preterm labor (tPTL) who receive antenatal corticosteroids (ACS) to better understand clinical decision-making. STUDY DESIGN: This retrospective cohort study consisted of patients seen in triage at an urban county hospital in 2021 for tPTL during pregnancy. Demographic variables (maternal age, race/ethnicity, and prior preterm delivery) and obstetrical variables (cervical dilation, effacement, membrane rupture, and tocolytic administration) were evaluated against the primary outcome of ACS administration. RESULTS: After exclusions, a cohort of 290 pregnant people with 372 unique encounters for tPTL remained. The mean maternal age was 26.7, and 15.6% of patients had a history of prior preterm birth. A total of 107 patients in 111 encounters received ACS, which were associated with lower body mass index (BMI), greater cervical dilation, greater effacement, membrane rupture, and more frequent contractions (all ps < 0.01). The mean presentation was at 33.5 weeks. Only 44% of those receiving ACS delivered within 7 days, compared with 11% of those who did not receive ACS (p < 0.001). Half (50%) of the patients receiving ACS delivered at >37 weeks. Adjusting for significant factors in the univariable analysis and limited to first encounter in triage, BMI (odds ratio: 0.91, 95% confidence interval: 0.87-0.95), cervical dilation ≥ 2 cm (2.49, 1.12-5.35), and cervical effacement ≥ 50% (4.80, 2.25-10.24) were significantly associated with patients receiving ACS. CONCLUSION: Greater cervical dilation and effacement and a lower BMI were associated with ACS administration, although most patients receiving ACS still did not deliver within 7 days. KEY POINTS: · In a cohort of 290 patients with 373 encounters for threatened preterm labor, 37% received ACS.. · We found that only 40% of those who received ACS delivered within 7 days and half went on to deliver at term.. · Cervical dilation ≥2 cm (odds ratio, 95% confidence interval: 2.49, 1.12-5.35) and effacement ≥50% (4.80, 2.25-10.24) were independently associated with receiving ACS..

2.
BMC Pregnancy Childbirth ; 21(1): 442, 2021 Jun 24.
Artículo en Inglés | MEDLINE | ID: mdl-34167497

RESUMEN

BACKGROUND: Betamethasone (BMZ) is used to accelerate fetal lung maturation in women with threatened preterm birth, but its efficacy is variable and limited by the lack of patient individualization in its dosing and administration. To determine sources of variability and potential opportunities for individualization of therapy, the objective of this study was to evaluate maternal factors associated with development of neonatal respiratory distress syndrome (RDS) in a cohort of women who received betamethasone. METHODS: This study prospectively enrolled women, gestational ages 23-34 weeks, who received betamethasone for threatened preterm birth. Maternal demographics, prenatal history, and neonatal outcomes were abstracted from hospital records. RDS was the primary outcome. Associations between RDS diagnosis and maternal demographics, prenatal history, and betamethasone dosing were evaluated in a case-control analysis and multivariable regression adjusted for gestational age at delivery. Secondary analyses limited the cohort to women who delivered within 1 or 2 weeks of betamethasone dosing. RESULTS: Of 209 deliveries, 90 (43 %) resulted in neonatal RDS. Within the overall cohort and controlling for gestational age at birth, RDS was only associated with cesarean births compared to vaginal births (adjusted OR 1.17 [1.06-1.29]). Route of delivery was also the only significant factor related to RDS in the 83 neonates delivered within 7 days of BMZ dosing. However, among 101 deliveries within 14 days of betamethasone dosing and controlling for gestational age at birth, women who experienced preterm premature rupture of membranes (PPROM) had lower RDS rates than those without PPROM (57.9 % vs. 80.2 %, adjusted OR 0.81 [0.67-0.99]). Maternal age, BMI, race, and ethnicity were not associated with RDS in the regression models. CONCLUSIONS: Of maternal characteristics analyzed, only delivery by cesarean was associated with neonatal RDS after antenatal betamethasone use.


Asunto(s)
Betametasona/uso terapéutico , Rotura Prematura de Membranas Fetales/prevención & control , Trabajo de Parto Prematuro/tratamiento farmacológico , Nacimiento Prematuro/prevención & control , Atención Prenatal/estadística & datos numéricos , Adulto , Estudios de Casos y Controles , Parto Obstétrico/estadística & datos numéricos , Demografía , Femenino , Edad Gestacional , Humanos , Recién Nacido , Embarazo , Estudios Prospectivos , Análisis de Regresión , Síndrome de Dificultad Respiratoria del Recién Nacido/etiología , Factores de Riesgo , Resultado del Tratamiento
3.
Pediatr Radiol ; 48(13): 1945-1954, 2018 12.
Artículo en Inglés | MEDLINE | ID: mdl-30178078

RESUMEN

BACKGROUND: Ultrasound (US) is the first-line imaging modality to assess the morbidly adherent placenta, but sensitivity and specificity are lacking. OBJECTIVE: This investigation aims to improve diagnostic accuracy with a comprehensive score using clinical history, US, and magnetic resonance imaging (MRI). MATERIALS AND METHODS: We conducted a retrospective cohort study of pregnant women who received both transvaginal US and MRI with suspicion for morbidly adherent placenta between 2009 and 2016. US was scored with the following metrics: (i) previa, (ii) hypervascularity, (iii) loss of retroplacental clear space and (iv) lacunae. MRI was evaluated for (i) intraparenchymal vessels, (ii) abnormally dilated vessels, (iii) fibrin deposition, (iv) placental bulge and (v) bladder dome irregularity. Bayesian analysis was used to estimate the probability of morbidly adherent placenta for a given score. Diagnostic testing parameters were calculated. RESULTS: Among the 41 women with concerning imaging, histologically identified disease was confirmed in 16. The probability of morbidly adherent placenta increased with the score. At the highest US score, the probability of disease was 63.7%. With the highest MRI score, the probability of adherent placentation was 90.5%. Combining the US and MRI findings had a sensitivity of 56% and a specificity of 92%. CONCLUSION: A combined scoring system using MRI and US may accurately identify patients at risk for morbidity associated with morbidly adherent placenta.


Asunto(s)
Imagen por Resonancia Magnética , Placenta Previa/diagnóstico por imagen , Retención de la Placenta/diagnóstico por imagen , Ultrasonografía Prenatal , Adulto , Teorema de Bayes , Femenino , Humanos , Embarazo , Estudios Retrospectivos , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad
5.
Am J Obstet Gynecol ; 214(2): 284.e1-284.e47, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26348374

RESUMEN

BACKGROUND: Inflammation is a proximate mediator of preterm birth and fetal injury. During inflammation several microRNAs (22 nucleotide noncoding ribonucleic acid (RNA) molecules) are up-regulated in response to cytokines such as interleukin-1ß. MicroRNAs, in most cases, fine-tune gene expression, including both up-regulation and down-regulation of their target genes. However, the role of pro- and antiinflammatory microRNAs in this process is poorly understood. OBJECTIVE: The principal goal of the work was to examine the inflammatory genomic profile of human decidual cells challenged with a proinflammatory cytokine known to be present in the setting of preterm parturition. We determined the coding (messenger RNA) and noncoding (microRNA) sequences to construct a network of interacting genes during inflammation using an in vitro model of decidual stromal cells. STUDY DESIGN: The effects of interleukin-1ß exposure on mature microRNA expression were tested in human decidual cell cultures using the multiplexed NanoString platform, whereas the global inflammatory transcriptional response was measured using oligonucleotide microarrays. Differential expression of select transcripts was confirmed by quantitative real time-polymerase chain reaction. Bioinformatics tools were used to infer transcription factor activation and regulatory interactions. RESULTS: Interleukin-1ß elicited up- and down-regulation of 350 and 78 nonredundant transcripts (false discovery rate < 0.1), respectively, including induction of numerous cytokines, chemokines, and other inflammatory mediators. Whereas this transcriptional response included marked changes in several microRNA gene loci, the pool of fully processed, mature microRNA was comparatively stable following a cytokine challenge. Of a total of 6 mature microRNAs identified as being differentially expressed by NanoString profiling, 2 (miR-146a and miR-155) were validated by quantitative real time-polymerase chain reaction. Using complementary bioinformatics approaches, activation of several inflammatory transcription factors could be inferred downstream of interleukin-1ß based on the overall transcriptional response. Further analysis revealed that miR-146a and miR-155 both target genes involved in inflammatory signaling, including Toll-like receptor and mitogen-activated protein kinase pathways. CONCLUSION: Stimulation of decidual cells with interleukin-1ß alters the expression of microRNAs that function to temper proinflammatory signaling. In this setting, some microRNAs may be involved in tissue-level inflammation during the bulk of gestation and assist in pregnancy maintenance.


Asunto(s)
Citocinas/genética , Decidua/metabolismo , Redes Reguladoras de Genes , MicroARNs/metabolismo , Parto/genética , ARN Mensajero/metabolismo , Células Cultivadas , Citocinas/efectos de los fármacos , Citocinas/inmunología , Decidua/citología , Decidua/efectos de los fármacos , Decidua/inmunología , Regulación hacia Abajo , Femenino , Regulación de la Expresión Génica , Humanos , Técnicas In Vitro , Interleucina-1beta/farmacología , MicroARNs/efectos de los fármacos , MicroARNs/inmunología , Proteínas Quinasas Activadas por Mitógenos/efectos de los fármacos , Proteínas Quinasas Activadas por Mitógenos/genética , Proteínas Quinasas Activadas por Mitógenos/inmunología , Análisis de Secuencia por Matrices de Oligonucleótidos , Parto/inmunología , Embarazo , ARN Mensajero/efectos de los fármacos , ARN Mensajero/inmunología , Reacción en Cadena en Tiempo Real de la Polimerasa , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética , Receptores Toll-Like/efectos de los fármacos , Receptores Toll-Like/genética , Receptores Toll-Like/inmunología , Regulación hacia Arriba
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA